[Bacampicillin, a new semisynthetic antibiotic for oral administration in the treatment of urinary tract infections (author's transl)].
The Authors report the results obtained administering 2.4 g/die of bacampicillin in a group of 30 patients suffering from both primary and secondary infections of the genito-urinary tracts. The antibiotic displayed excellent tolerability and therapeutic effectiveness, determining in almost all the treated cases either the resolution or, at least, significant improvement of the inflammatory course; only two patients, as a matter of fact, showed mild side effects.
D000328:Adult; D000368:Aged; D000667:Ampicillin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001799:Blood Sedimentation; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004361:Drug Tolerance; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011512:Proteus Infections / Q000188:drug therapy; D011552:Pseudomonas Infections / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000209:etiology
D000667:Ampicillin
La bacampicillina, nuova penicillina semisintetica per uso orale, nella terapia delle infezioni urinarie.